Protocol for a pragmatic randomised controlled feasibility study of


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
20 May 2024
Historique:
medline: 22 5 2024
pubmed: 22 5 2024
entrez: 21 5 2024
Statut: epublish

Résumé

Multiple sclerosis (MS) causes a wide variety of symptoms. Loss of income due to sickness and early retirement comprise one-third of the total cost of MS in Australia. An intervention that maximises work productivity and keeps people with MS in the workforce for longer could provide a large societal cost saving and improve quality of life. The aim is to test the feasibility of delivering and evaluating a 10-week digitally delivered intervention called ' A parallel-arm randomised controlled feasibility study, comparing those randomised to receive the MS WorkSmart package plus usual care (n=20) to those receiving usual care only (n=20). Australians with MS, aged 18-60 years, who are employed, and self-report work instability will be recruited from the Australian MS Longitudinal Study. Online surveys, at baseline and 1-month postintervention, will include MS-related work productivity loss and risk of job loss, MS work behaviour self-efficacy, health-related quality of life, fatigue severity, MS symptom impact on work, intention to retire due to MS, MS-related work difficulties, and awareness and readiness for change at work. Qualitative feedback will be obtained via a semistructured survey following the intervention (for participants) and via interviews (coaches). Analyses will be primarily descriptive and focus on the feasibility and acceptability of the intervention and study procedures. Progression criteria will guide decisions around whether to progress to a full trial. The study has been approved by the University of Tasmania Human Research Ethics Committee (H0024544). Findings will be disseminated via publication in peer-reviewed journals, conference presentations and community presentations. ACTRN12622000826741.

Identifiants

pubmed: 38772578
pii: bmjopen-2023-079644
doi: 10.1136/bmjopen-2023-079644
doi:

Types de publication

Journal Article Clinical Trial Protocol

Langues

eng

Sous-ensembles de citation

IM

Pagination

e079644

Informations de copyright

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Ingrid van der Mei (I)

Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia ingrid.vandermei@utas.edu.au.

Sarah Thomas (S)

Faculty of Health and Social Sciences, Bournemouth University, Poole, UK.

Sue Shapland (S)

Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia.

Laura L Laslett (LL)

Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia.

Bruce V Taylor (BV)

Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia.

Alisée Huglo (A)

Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia.

Cynthia Honan (C)

School of Psychological Sciences, College of Health and Medicine, University of Tasmania, Hobart, Tasmania, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH